

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2024/211601 A9

(43) International Publication Date
10 October 2024 (10.10.2024)

- (51) International Patent Classification:
A61K 35/26 (2015.01) *A61K 35/545* (2015.01)
- (21) International Application Number:
PCT/US2024/023120
- (22) International Filing Date:
04 April 2024 (04.04.2024)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/457,314 05 April 2023 (05.04.2023) US
- (71) Applicant: **THYMMUNE THERAPEUTICS, INC.**
[US/US]; 238 Main Street, Cambridge, Massachusetts
02142 (US).
- (72) Inventors: **LIM, Bing**; c/o THYMMUNE THERA-
PEUTICS, INC., 238 Main Street, Cambridge, Massa-
chusetts 02142 (US). **WANG, Stan**; c/o THYMMUNE
THERAPEUTICS, INC., 238 Main Street, Cambridge,
Massachusetts 02142 (US). **GERAMI-NAINI, Behzad**;
c/o THYMMUNE THERAPEUTICS, INC., 238 Main

Street, Cambridge, Massachusetts 02142 (US). **DU, Qi-
umei**; c/o THYMMUNE THERAPEUTICS, INC., 238
Main Street, Cambridge, Massachusetts 02142 (US). **BEA-
MAN, JR., Henry Thomas**; c/o THYMMUNE THERA-
PEUTICS, INC., 238 Main Street, Cambridge, Massachu-
setts 02142 (US). **SCHWARZ, Benjamin A.**; c/o THYM-
MUNE THERAPEUTICS, INC., 238 Main Street, Cam-
bridge, Massachusetts 02142 (US).

(74) Agent: **CAVAZOS, Alexandra** et al.; DLA PIPER LLP
US, 4365 Executive Drive, Suite 1100, SAN DIEGO, Cali-
fornia 92121-2133 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: THYMIC CELL COMPOSITIONS AND METHODS OF MAKING




FIG. 1

(57) Abstract: The present disclosure provides thymic cells, thymic organoids, and animal models comprising such thymic cells and thymic organoids. It also provides methods for inducing differentiation of pluripotent stem cells into definitive endoderm (DE), anterior foregut endoderm (AFE), ventral pharyngeal endoderm (VPE), thymic epithelial progenitor (TEP) cells, thymic epithelial cells (TECs) and thymic organoids *in vitro* and *in vivo*.

[Continued on next page]

WO 2024/211601 A9

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

28 November 2024 (28.11.2024)

(15) Information about Correction:

see Notice of 28 November 2024 (28.11.2024)